Real-world study on dapagliflozin usage in patients with Heart Failure (HF) in Germany - EvolutionHF-DE

Study identifier:D1699R00050

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

Early treatment of heart failure: a non-interventional study program of patients with heart failure and initiated on dapagliflozin (EVOLUTION-HF DEallEF)

Medical condition

Heart Diseases, cardiovascular diseases

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

1000

Study type

Observational

Age

18 Years - 130 Years

Date

Study Start Date: 30 Apr 2024
Estimated Primary Completion Date: 30 Sept 2026
Estimated Study Completion Date: 30 Sept 2026

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Mar 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria